The DOI matches its Crossref record.
Antihistamines in urticaria
Abstract
Urticaria is one of the most common and, in its chronic course, excruciating dermato‐allergic diseases. Apart from the dermatological diagnosis, the identification and evaluation of causal triggering factors is of utmost importance. Here a ‘three‐step guideline’ (according to Ring and Przybilla) has gained acceptance, ranging from a general basic examination via an intensive investigation until oral provo‐cation tests for food allergy and oral provocation tests for idiosyncrasy (OPTI) against food additives. Apart from true IgE‐mediated allergies, pseudo‐allergic reactions against food additives as well as food contents represent a major problem in chronic urticaria. Recently gastric mucosal colonization with Helicobacter pylori as the trigger of chronic urticaria has received attention. New patho‐physiological concepts describe autoantibodies that are directed either against IgE or against the high‐affinity IgE‐receptor on the surface of mast cells and basophil leucocytes. In the intradermal test with autologous serum positive wheal and flare reactions can be observed (Greaves’ test). In many patients with chronic urticaria considerable psychosomatic involvement is also observed. Histamine is one of the major mediators of most forms of urticaria although in some cases, especially physical urticaria, other mediators seem to play a role. Therefore antihistamines, and mainly H 1 antihistamines, are the mainstay of antiurticaria therapy. Some studies have shown a benefit of combined H 1‐ and H 2‐antagonist treatment in special forms of urticaria namely urticaria factitia. Similarily pretreatment with combined H 1 and H 2 antagonists has been proven to reduce effectively the frequency of pseudo‐allergic reaction to some histamine‐releasing drugs used in radiology or surgery. More than 50 years after the first introduction of an antihistamine into allergy therapy, antihistamines still represent modern and exciting agents contributing to the continuous improvement of antiallergic therapy. Antihistamine therapy can be performed with either the classical or second generation antihistamines. Classical antihistamines are connected with considerable side‐effects especially sedation and anticholinergic effects. New non‐sedating antihistamines have been developed that do not cross the blood–brain barrier. The efficacy of mizolastine, a new non‐sedating H 1 antagonist, has been evaluated in several placebo‐controlled and comparative clinical trials. Overall, mizolastine 10 mg/day was found to be significantly more effective than placebo and as effective as other second generation antihistamine drugs in the management of patients with chronic urticaria, with a rapid and sustained action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
The epidemic of allergy and asthma
Holgate, S. T. (1999) · Nature · doi:10.1038/35037000 · Cited by 586
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A. M., Grattan, C. E. H., Kapp, A., Maurer, M., Merk, H. F., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02178.x · Cited by 527
EAACI/GA2LEN/EDF guideline: management of urticaria
Zuberbier, T., Bindslev‐Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A., Maurer, M., Merk, H. F., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2005.00962.x · Cited by 461
Till, S. J., Francis, J. N., Nouri-Aria, K., & Durham, S. R. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.03.024 · Cited by 434
Metadata
- Authors
- Ring, J., Brockow, K., Ollert, M., & Engst, R.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 1999-03
- Volume
- 29
- Issue
- s1
- Pages
- 31-37
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W1994276227
- Cited by
- 186
- References
- 0
- FWCI
- 14.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihistamines in urticaria. https://app.cochat.ai/papers/10.1046/j.1365-2222.1999.00006.x
- The paper
- Ring, J., Brockow, K., Ollert, M., & Engst, R. (1999). Antihistamines in urticaria. Clinical & Experimental Allergy. https://doi.org/10.1046/j.1365-2222.1999.00006.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.